Trump Administration Authorizes Medicare Test Program for CBD

The Trump administration has authorized a test program that will provide free cannabidiol, commonly known as CBD, to selected Medicare patients. The initiative aims to determine whether the cannabis-derived compound can alleviate specific symptoms among older adults and lower overall health care spending.

Officials will monitor participant outcomes during the trial period. CBD is a non-psychoactive compound found in cannabis. Unlike THC, it does not produce intoxication. The compound has been marketed for potential relief of pain, anxiety, inflammation and sleep issues, though scientific evidence on its effectiveness for many claimed uses remains limited.

The test program represents an early federal exploration of covering CBD under Medicare. Results from the trial could inform future decisions on whether to expand access or include the compound in broader insurance coverage for older Americans. Participation will be limited to certain Medicare beneficiaries who meet eligibility criteria that have not been fully detailed.

The program will track health outcomes and cost data to assess any measurable benefits.

Administrators intend to measure whether providing free CBD leads to reduced use of other medications or fewer medical visits among participants. The test will also evaluate patient-reported symptom relief over the course of the study. If the program demonstrates clear benefits, it could open the door to wider Medicare coverage of CBD products.

Conversely, lack of measurable improvement or evidence of limited efficacy could constrain future expansion. The authorization comes as public interest in cannabis-derived wellness products has grown among older populations. Medicare serves more than 65 million Americans, the majority of whom are aged 65 and older.